# Neuralink — Healthcare Investment Intelligence

> medical_device · Series C+. MedFuel Intel profile as of 2026-06-12.

Neuralink is developing implantable brain-computer interfaces (BCIs) using tiny electrodes and a surgical robot for high-bandwidth neural recording to treat conditions like paralysis from spinal cord injury, ALS, or stroke. The company has FDA approval for human clinical trials, with ongoing trials and preclinical success in pigs and monkeys, and plans for advanced multi-implant systems by 2028.

## Key facts (as of 2026-06-12)
- Sector: medical_device
- Stage: Series C+
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-27. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.